An update on the pharmacotherapeutic strategies for the treatment of dysthymic disorder: a systematic review

References

• Gilmer WS, Trivedi MH, Rush AJ, et al. Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. Acta Psychiatr Scand. 2005;112(6):425–433. doi: 10.1111/j.1600-0447.2005.00633.x
   PubMed Web of Science ®Google Scholar
• Dunner DL. Dysthymia and double depression. Int Rev Psychiatry. 2005;17(1):3–8. doi: 10.1080/09540260500064983
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of Mental disorders. Am Psychiatric Ass. 2013 May 22. Epub Ahead Of Print 10.1176/appi.books.9780890425596
   Google Scholar
• Klein DN. Chronic depression. Curr Dir Psychol Sci. 2010;19(2):96–100. doi: 10.1177/0963721410366007
   Web of Science ®Google Scholar
• Kessler RC. Lifetime and 12-month prevalence of DSM-III-R Psychiatric disorders in the United States. Arch Gen Psychiatry. 1994;51(1):8. doi: 10.1001/archpsyc.1994.03950010008002
   PubMed Web of Science ®Google Scholar
• Sansone RA, Sansone LA. Dysthymic disorder: forlorn and overlooked? Psychiatry (Edgmont). 2009;6:46–51.
   PubMedGoogle Scholar
• Carta MG, Paribello P, Nardi AE, et al. Current pharmacotherapeutic approaches for dysthymic disorder and persistent depressive disorder. Expert Opin Pharmacother. 2019;20(14):1743–1754. doi: 10.1080/14656566.2019.1637419
   PubMed Web of Science ®Google Scholar
• Klein DN. Five-year course and outcome of dysthymic disorder: a prospective, naturalistic follow-up study. Am J Psychiatry. 2000;157(6):931–939. doi: 10.1176/appi.ajp.157.6.931
   PubMed Web of Science ®Google Scholar
• Klein DN, Shankman SA, Rose S. Dysthymic disorder and double depression: prediction of 10-year course trajectories and outcomes. J Psychiatr Res. 2008;42(5):408–415. doi: 10.1016/j.jpsychires.2007.01.009
   PubMed Web of Science ®Google Scholar
• Hellerstein DJ, Agosti V, Bosi M, et al. Impairment in psychosocial functioning associated with dysthymic disorder in the NESARC study. J Affect Disord. 2010;127(1–3):84–88. doi: 10.1016/j.jad.2010.04.013
   PubMed Web of Science ®Google Scholar
• Kamenov K, Twomey C, Cabello M, et al. The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis. Psychol Med. 2017;47(3):414–425. doi: 10.1017/S0033291716002774
   PubMed Web of Science ®Google Scholar
• Jobst A, Brakemeier E-L, Buchheim A, et al. European Psychiatric Association Guidance on psychotherapy in chronic depression across Europe. Eur Psychiatry. 2016;33(1):18–36. doi: 10.1016/j.eurpsy.2015.12.003
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci. 2003;100(24):14293–14296. doi: 10.1073/pnas.2336126100
   PubMed Web of Science ®Google Scholar
• Kocsis JH, Leon AC, Markowitz JC, et al. Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. J Clin Psychiatry. 2009;70(3):354–361. doi: 10.4088/JCP.08m04371
   PubMed Web of Science ®Google Scholar
• MacQueen G, Santaguida P, Keshavarz H, et al. Systematic review of clinical practice guidelines for failed antidepressant treatment response in major depressive disorder, dysthymia, and subthreshold depression in adults. Can J Psychiatry. 2017;62(1):11–23. doi: 10.1177/0706743716664885
   PubMed Web of Science ®Google Scholar
• Cleare A, Pariante C, Young A, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459–525. doi: 10.1177/0269881115581093
   PubMed Web of Science ®Google Scholar
• Kocsis JH, Gelenberg AJ, Rothbaum B, et al. Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatment. J Affect Disord. 2008;110(1–2):55–61. doi: 10.1016/j.jad.2008.01.002
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;71. doi: 10.1136/bmj.n71
   Web of Science ®Google Scholar
• Richardson WS, Wilson MC, Nishikawa J, et al. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123:A12–3. doi: 10.7326/ACPJC-1995-123-3-A12
   PubMedGoogle Scholar
• Ravindran AV, Cameron C, Bhatla R, et al. Paroxetine in the treatment of dysthymic disorder without co-morbidities: a double-blind, placebo-controlled, flexible-dose study. Asian J Psychiatr. 2013;6:157–161. doi: 10.1016/j.ajp.2012.10.004
   PubMedGoogle Scholar
• Yang J, Hellerstein DJ, Chen Y, et al. Gray matter reorganization underpinnings of antidepressant treatment of persistent depressive disorder. Eur Neuropsychopharmacol. 2021;43:129–138. doi: 10.1016/j.euroneuro.2020.12.009
   PubMed Web of Science ®Google Scholar
• Bersani G, Meco G, Denaro A, et al. L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. Eur Neuropsychopharmacol. 2013;23(10):1219–1225. doi: 10.1016/j.euroneuro.2012.11.013
   PubMed Web of Science ®Google Scholar
• Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017 May;4(5):409–418. doi: 10.1016/S2215-0366(17)30015-9
   PubMed Web of Science ®Google Scholar
• Ruhe HG, Mocking RJT, Figueroa CA, et al. Emotional biases and recurrence in major depressive disorder. Results of 2.5 years follow-up of drug-free cohort vulnerable for recurrence. Front Psychiatry. 2019 Mar 28;10:145. doi: 10.3389/fpsyt.2019.00145
   PubMed Web of Science ®Google Scholar
• Chiechio S, Canonico PL, Grilli M. L-Acetylcarnitine: a mechanistically distinctive and potentially rapid-acting antidepressant drug. Int J Mol Sci. 2017 Dec 21;19(1):11. doi: 10.3390/ijms19010011
   PubMed Web of Science ®Google Scholar
• Adler LA, Reingold LS, Morrill MS, et al. Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep. 2006;8:409–415. doi: 10.1007/s11920-006-0044-9
   PubMedGoogle Scholar
• Vance A, Winther J. ADHD and dysthymic disorder: toward understanding this common comorbidity in children and adolescents. Curr Atten Disord Rep. 2009;1(4):145–151. doi: 10.1007/s12618-009-0020-5
   Google Scholar
• Pary R, Scarff JR, Jijakli A, et al. A review of psychostimulants for adults with depression. Fed Pract. 2015 Apr;32(Suppl 3):30S–37S.
   PubMedGoogle Scholar
• Aschauer HN. [Dysthymia: a chronic illness and its treatment]. Wien Med. 1999 Jan 1;149(18):503–510.
   PubMedGoogle Scholar
• Vaughan B, Goldstein MH, Alikakos M, et al. Frequency of reporting of adverse events in randomized controlled trials of psychotherapy vs. psychopharmacotherapy. Compr Psychiatry. 2014;55(4):849–855. doi: 10.1016/j.comppsych.2014.01.001
   PubMed Web of Science ®Google Scholar
• von Wolff A, Hölzel LP, Westphal A, et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord. 2013;144(1–2):7–15. doi: 10.1016/j.jad.2012.06.007
   PubMed Web of Science ®Google Scholar